Fig. 3: BRD/BET proteins are required for adaptive ErbB3 upregulation following BRAF/MEK inhibitors treatment in BRAF-mutant melanoma. | British Journal of Cancer

Fig. 3: BRD/BET proteins are required for adaptive ErbB3 upregulation following BRAF/MEK inhibitors treatment in BRAF-mutant melanoma.

From: Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

Fig. 3: BRD/BET proteins are required for adaptive ErbB3 upregulation following BRAF/MEK inhibitors treatment in BRAF-mutant melanoma.The alternative text for this image may have been generated using AI.

a Scatter plots with trend lines of BRD2 mRNA versus ERBB3 mRNA z-score data from BRAF-mutant TCGA cutaneous melanoma samples (n = 142). b Scatter plots with trend lines of BRD4 mRNA versus ERBB3 representative Western blots of three (n = 3) independent experiments for ErbB3, PDGFR-β, and AXL after BRD2 and BRD4 knockdown, and c 24 h of treatment using BRAFi/MEKi (dabrafenib, 50 nM + trametinib, 5 nM) for the BRAF-mutant human melanoma cell lines, 1205Lu and M238. The siRNA scramble control (siCTRL), BETi (PLX51107, 2 ÎĵM) single agent, and BRAFi/MEKi/BETi treatments for 24 h were used as controls.

Back to article page